-
Novel approaches could open therapeutic avenues for inflammatory arthritis
Adam Mor, MD, PhD, Assistant Professor of Medicine and Pathology at New York University School of Medicine, will discuss the role of T cells in rheumatoid arthritis.
-
Systemic sclerosis patients often face gastrointestinal woes
Tracy M. Frech, MD, MS, director of the Systemic Sclerosis Clinic at the University of Utah and a rheumatologist in the Veterans Affairs Salt Lake City Health Care System, will lead the clinical symposium Systemic Sclerosis: Assessment and Treatment of Gastrointestinal Manifestations, which starts at 2:30 pm Tuesday.
-
Evolving evidence creates novel treatment opportunities in axial spondyloarthritis
Dirk Elewaut, MD, PhD, Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology at Ghent University Hospital, Belgium, will discuss the role of the interleukin 23/interleukin 17 (IL23/IL17) axis in the pathogenesis of axial spondyloarthritis.
-
Annual Meeting opens with look at workforce, big data, and mobile tools
This year’s ACR/ARHP Annual Meeting formally started Saturday afternoon with the traditional ACR/ARHP Opening Lecture and Awards. ACR President Joan M. Von Feldt, MD, MSEd, opened the session with a look at what’s happening in the field and at the association.
-
Experts review year’s rheumatologic research
Sunday morning’s Year in Review session brought together two experts who culled research published over the past year in clinical and basic science to selected studies they felt showed major trends and significant insights to the development and treatment of rheumatologic diseases, including rheumatoid arthritis, osteoarthritis, and lupus.
-
Data mining could lead to therapy advances
In the past 50 years, only one new therapy has been approved for the treatment of lupus. Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL Bio-Solutions, Charlottesville, VA, works to change that.
-
Renowned international researcher to review latest developments in antibody-based therapies
For the past 20 years, investigator John D. Isaacs, MD, PhD, FRCP, Professor of Clinical Rheumatology at Newcastle University, Newcastle upon Tyne, United Kingdom, has focused his work on the potential of novel immunotherapies to treat rheumatoid arthritis — ranging from target identification to early and late-stage clinical trials.
-
Humanities play an important role in healthcare, says ARHP keynote speaker
The humanities come in many forms — literature, music, art, and nature, to name a few — and give perspective on what it means to be human. They are also rich in what they can offer patients and healthcare professionals, said ARHP keynote speaker Paulette C. Hahn, MD, on Sunday morning.
-
Genomic, epigenomic research into underpinnings of RA show therapeutic promise
This year’s recipient of the Rheumatology Research Foundation Paul Klemperer, MD, Memorial Lectureship, Gary Firestein, MD, dedicated his lecture Sunday to an explanation of research into how the human genome, epigenome, and environmental factors lead to the development and progression of RA and how this research can improve therapy.
-
New guideline for glucocorticoid-induced osteoporosis coming
A Sunday afternoon clinical symposium described how the draft guideline, which has not yet been approved by the ACR, expands on the 2010 guideline to consider the fracture risk and treatment options among new patient populations and how the recommendations vary based on glucocorticoid dose.